Goal 1: Prevent and
Effectively Treat Alzheimer’s Disease by 2025
Research
continues to expand our understanding of the causes of, treatments for, and
prevention of Alzheimer’s disease. Basic research elucidates the molecular and
cellular process underlying AD, allowing the identification of potential
targets for intervention. Through the drug development process and the
translation of behavioral interventions, treatments are tested in preclinical
experiments for their effectiveness. Promising interventions are further
refined and tested to ensure they are safe and effective for the public. While
the ultimate goals are to develop effective prevention and treatment modalities
by 2025, ongoing research and clinical inquiry can inform our ability to delay
onset of Alzheimer’s disease, minimize its symptoms, and delay its progression.
Under this goal, HHS will prioritize and accelerate the pace of scientific
research and ensure that as evidence-based solutions are identified they are
quickly translated, put into practice, and brought to scale so that individuals
with Alzheimer’s disease can benefit from increases in scientific knowledge.
Strategy 1.A: Identify Research Priorities and Milestones
Research
agencies undertake research planning processes on an ongoing basis, but a
special effort is needed to identify the priorities and milestones to achieve
Goal 1 and ensure that appropriate stakeholders are involved in the planning
process. In May 2012, the National Institute on Aging (NIA) of the National
Institutes of Health will convene a research summit to provide expert input
into identification of research priorities, to explore public and private
research collaborations, and to establish strategies and milestones for an
ambitious plan to slow progression, delay onset, and prevent Alzheimer’s
disease. The summit will include national and international experts in
Alzheimer’s disease and dementia research, public and private stakeholders, and
members of the Advisory Council on Alzheimer’s Research, Care, and Services.
Summit proceedings will be open to the public.
Strategy 1.B: Enhance Scientific Research Aimed at Preventing and
Treating Alzheimer’s Disease
HHS
and its Federal partners will continue to aggressively conduct clinical trials
on pharmacologic and non-pharmacologic ways to prevent Alzheimer’s disease and
manage and treat its symptoms. HHS will build on recent advances and expand
research to identify molecular and cellular mechanisms and genetic research to
identify risk and protective factors. To achieve this strategy, new
partnerships and outreach efforts may be needed to ensure that enough people
are enrolled in clinical trials to examine the effectiveness of promising
interventions.
Strategy 1.C: Accelerate Efforts to Identify Early and
Presymptomatic Stages of Alzheimer’s Disease
Significant
advances in the use of imaging and biomarkers in brain, blood, and spinal
fluids have made it possible to detect the onset of Alzheimer’s disease, track
its progression and monitor the effects of treatment in people with the
disease. Without these advances, these neurodegenerative processes could only
be evaluated in non-living tissues. Accelerated research will improve and
expand the application of biomarkers in research and practice. These advances
have shown that the brain changes that lead to Alzheimer’s disease begin up to
10 years before symptoms. Identifying imaging and other biomarkers in
presymptomatic people will facilitate earlier diagnoses in clinical settings,
as well as aid in the development of more efficient interventions to slow or
delay progression.
Strategy 1.D: Coordinate Research with International Public and
Private Entities
To
facilitate communication and collaboration, build synergy, and leverage
resources, it is imperative that research across nations and across funders be
coordinated. All funders could benefit from a comprehensive inventory of
research investments to address AD. Similarly, better international
coordination may help leverage resources and expand the impact of research
findings.
Strategy 1.E: Facilitate Translation of Findings into Medical
Practice and Public Health Programs
Currently,
promising research and interventions are published in the research literature and
presented at scientific meetings. Additional steps are needed to highlight
promising findings and to facilitate dissemination and implementation of
effective interventions to the general public, medical practitioners, industry,
and public health systems quickly and accurately. This may require new
partnerships within the Federal Government and with the private sector, and
outreach through new mechanisms.
Goal 2: Enhance Care
Quality and Efficiency
Providing
all people with Alzheimer’s disease with the highest-quality care in the most
efficient manner requires a multi-tiered approach. High-quality care requires
an adequate supply of professionals with appropriate skills, ranging from
direct-care workers to community health and social workers to primary care
providers and specialists. High-quality care should be provided from the point
of diagnosis through the end-of-life and in settings including people’s homes,
doctor’s offices, hospitals, and nursing homes. Care quality should be measured
accurately and coupled with quality improvement tools. Further, given the
complex care needs of people with Alzheimer’s disease, high-quality and
efficient care is dependent on smooth transitions between care settings and
coordination among health and long-term care service providers.
Strategy 2.A: Build a Workforce with the Skills to Provide
High-Quality Care
The
workforce that cares for people with Alzheimer’s disease includes health and
long-term care providers such as primary care physicians; specialists such as
neurologists, geriatricians, and psychiatrists; community health workers;
social workers; and direct-care workers like home health aides and certified
nursing assistants, who provide care at home or in long-term care facilities.
Major efforts by both VA and the Health Resources and Services Administration
(HRSA), including expanded training opportunities created in the Affordable
Care Act, support geriatric training for physicians, nurses, and other health
workers.1 Enhanced specialist training is also
needed to prepare these practitioners for the unique challenges faced by
patients with Alzheimer’s disease. Work is needed to expand the capacity of the
primary care community to care for patients with Alzheimer’s disease and
dementia-specific capabilities within the direct-care workforce need to be
expanded and enhanced.
Strategy 2.B: Ensure Timely and Accurate Diagnosis
Far
too many people with Alzheimer’s disease are not diagnosed until their symptoms
have become severe.2 Timely diagnosis gives people with
the condition and their families time to plan and prepare for the future,
leading to more positive outcomes for both.3, 4 For many, the inability to access
health care due to a lack of insurance is a major concern. This is particularly
important for individuals with younger-onset disease who may not yet be
eligible for Medicare. Much of that insecurity will be alleviated as the
Affordable Care Act, with its elimination of pre-existing conditions
limitations, is implemented. Even with access to affordable care for
individuals, the health care workforce needs tools that can help ensure timely
and accurate diagnoses. Research has helped identify some assessment tools that
can be used to rapidly assess patients showing signs and symptoms of
Alzheimer’s disease and to help health care providers make a diagnosis or refer
for further evaluation.5
Strategy 2.C: Educate and Support Patients and Families Upon
Diagnosis
Often,
even though a physician has identified cognitive impairment, the patient and
his or her family are not told of the diagnosis.6 Further, once a diagnosis is made
and disclosed, as few as half of patients and families receive counseling,
support, or information about next steps.7 This information is important,
especially for early-stage patients who experience positive outcomes when
physicians are involved in planning and advance care counseling.8
Strategy 2.D: Identify and Implement High-Quality Dementia Care
Guidelines and Measures Across Care Settings
Guidelines
for delivery of high-quality care and measures of quality are needed to ensure
people with Alzheimer’s disease receive high-quality care in the many different
settings where they are treated. These guidelines should be tailored to the
stages of the disease and cover the myriad care settings in which care is
delivered, such as in the home, physician’s office, and long-term care
facility. These guidelines should also take into account how care might be
modified in the context of co-occurring chronic conditions in people with
Alzheimer’s disease. Quality measures should be based on such guidelines and
track whether recommended care is being provided.
Strategy 2.E: Ensure that People with Alzheimer’s Disease
Experience Safe and Effective Transitions Between Care Settings and Systems
A
transition between providers and care settings is a complex time of care
delivery for all patients but especially for frail elders or other individuals
with Alzheimer’s disease. Transitions include moves into acute care hospitals,
from hospitals to post-acute settings such as skilled nursing facilities or the
home, or from nursing facilities to hospitals. People with Alzheimer’s disease
are at high risk of adverse events due to poor communication and other care
process deficiencies during their frequent transitions.9
Strategy 2.F: Advance Coordinated and Integrated Health and
Long-Term Care Services and Supports for Individuals Living with Alzheimer’s
Disease
Coordinating
the care received by people with Alzheimer’s disease from different providers
can help reduce duplication and errors and improve outcomes.10 Despite a general consensus that
care coordination is important, more research is needed to determine how best
to provide such care in a high-quality and cost-efficient manner. These answers
will help in the implementation of care coordination models for people with
Alzheimer’s disease.
Strategy 2.G: Improve Care for Populations Disproportionally
Affected by Alzheimer’s Disease
Three
groups of people are unequally burdened by Alzheimer’s disease: People with
younger-onset Alzheimer’s disease, racial and ethnic minorities, and people
with intellectual disabilities. Approximately 200,000 Americans have younger-onset
Alzheimer’s disease, which is characterized by symptoms prior to age 60.
Because Alzheimer’s disease primarily affects older adults, the younger
population faces unique challenges with diagnosis, care, and stigma. Other
populations disproportionally burdened by Alzheimer’s disease are racial and
ethnic minorities who are at greater risk for developing Alzheimer’s disease
and face barriers to care after onset. Finally, people with certain
intellectual disabilities almost always develop Alzheimer’s disease as they
age.
Goal 3: Expand Patient
and Family Support
People
with Alzheimer’s disease and their families need supports that go beyond the
care provided in formal settings such as doctor’s offices, hospitals, or
nursing homes. Families and other informal caregivers play a central role here.
Supporting people with Alzheimer’s disease and their families and caregivers
requires giving them the tools that they need, helping to plan for future
needs, and ensuring that safety and dignity are maintained.
Strategy 3.A: Ensure Receipt of Culturally Sensitive Education, Training,
and Support Materials
Caregivers
report that they feel unprepared for some of the challenges of caring for a
person with Alzheimer’s disease--for example, caring for a loved one with sleep
disturbances, behavioral changes, or in need of physical assistance can be an
enormous challenge.11 Giving caregivers the information
and training that they need in a culturally sensitive manner helps them better
prepare for these and other challenges. Examples of potential actions under
this strategy include identifying the areas of training and educational needs,
identifying and creating culturally-appropriate materials, distributing these
materials to caregivers, and using information technology to support persons
with Alzheimer’s disease and their caregivers.
Strategy 3.B: Enable Family Caregivers to Continue to Provide Care
While Maintaining Their Own Health and Well-Being
Even
though informal caregivers usually prefer to provide care to their loved ones
in their home or other community settings, eventually the round-the-clock care
needs of the person with Alzheimer’s disease often necessitate nursing home
placement. While they are providing care, supports for families and caregivers
can help lessen feelings of depression and burden and help delay nursing home
placement.12, 13, 14 Examples of actions to further
support informal caregivers are identifying their unmet support needs;
developing, disseminating and expanding interventions; and highlighting
supports during crisis situations.
Strategy 3.C: Assist Families in Planning for Future Long-Term
Care Needs
The
vast majority of people do not think about or plan for the long-term services
and supports they will need until they experience a disability or Alzheimer’s
disease. Many Americans incorrectly believe that Medicare will cover most of
the costs of these supportive services.15, 16 Unfortunately, by the time care is
needed, it is difficult to get coverage in the private long-term care insurance
market, and options are limited.17 Educating people about their
potential need for long-term services and supports and the significant
advantages of planning ahead for these services encourages timely preparation.
Planning ahead can help ensure that individuals with Alzheimer’s disease receive
care in the setting they prefer and that their dignity is maintained.
Strategy 3.D: Maintain the Dignity, Safety, and Rights of People
with Alzheimer’s Disease
People
with Alzheimer’s disease are particularly vulnerable to financial exploitation,
physical or emotional abuse, and neglect both at home and in residential care
facilities.18 Reports of elder abuse are handled
by state Adult Protective Services, which is charged with responding to and
resolving alleged abuse. State survey and certification agencies investigate
abuse in licensed facilities, which may include nursing homes, assisted living
facilities, and board and care homes. AoA’s National Long-Term Care Ombudsmen
are advocates for residents of nursing homes, board and care homes, assisted
living facilities, and similar adult care facilities and can help address
issues related to potential abuse or neglect.
Goal 4: Enhance Public
Awareness and Engagement
Most
of the public is aware of Alzheimer’s disease: more than 85 percent of people
surveyed can identify the disease and its symptoms. Alzheimer’s disease is also
one of the most-feared health conditions. Yet there are widespread and
significant public misperceptions about diagnosis and treatment.19 These misperceptions lead to
delayed diagnosis and to people with the disease and their caregivers feeling
isolated and stigmatized. Enhancing public awareness and engagement is an
important goal because it forms the basis for advancing the other goals of the
National Plan. A better understanding of Alzheimer’s disease will help engage
stakeholders who can help address the challenges faced by people with the
disease and their families. These stakeholders include a range of groups such
as health care providers who care for people with Alzheimer’s disease and their
caregivers, employers whose employees request flexibility to care for a loved one
with the disease, women’s and other groups whose members are caregivers, and
broader aging organizations. The strategies under this goal are designed to
educate these and other groups about the disease.
Strategy 4.A: Educate the Public about Alzheimer’s Disease
Greater
public awareness of Alzheimer’s disease can encourage families to seek
assessment, reduce isolation and misunderstanding felt by caregivers, and help
link people in need to accurate information, resources and services.
Strategy 4.B: Work with State and Local Governments to Improve
Coordination and Identify Model Initiatives to Advance Alzheimer’s Disease
Awareness and Readiness Across the Government
State
and local governments are working to help address challenges faced by people
with Alzheimer’s disease and their caregivers. Nineteen states and a handful of
local entities have published plans to address Alzheimer’s disease that cover
many of the same issues as the National Plan.20 Leveraging the available resources
and programs across these levels of government will aid in the success of these
efforts.
Goal 5: Improve Data To
Track Progress
The
Federal Government is committed to better understanding Alzheimer’s disease and
its impact on people with the disease, families, the health and long-term care
systems, and society as a whole. HHS will make efforts to expand and enhance
data infrastructure and make data easily accessible to federal agencies and
other researchers. This data infrastructure will help HHS in its multi-level
monitoring and evaluation of progress on the National Plan.
Strategy 5.A: Enhance HHS’ Ability to Track Progress
To
address policy questions and plan and evaluate new initiatives, the Federal
Government needs improved data on people with Alzheimer’s disease, their
caregivers, and the care and supports that they use.
Strategy 5.B: Monitor Progress on the National Plan
The
National Plan is intended to be a roadmap for accomplishing its five goals. It
is a document that is designed to be updated regularly. HHS is committed to
tracking progress and incorporating findings into an updated National Plan
annually.
Appendix: List of
Participating Departments and Agencies
|
ACF
|
Administration for
Children and Families
|
|
ADD
|
Administration on
Developmental Disabilities
|
|
AoA
|
Administration on
Aging
|
|
AHRQ
|
Agency for Healthcare
Research and Quality
|
|
ASPA
|
Assistant Secretary of
Public Affairs
|
|
ASPE
|
Assistant Secretary
for Planning and Evaluation
|
|
CDC
|
Centers for Disease
Control and Prevention
|
|
CMMI
|
Center for Medicare
and Medicaid Innovation Center
|
|
CMS
|
Centers for Medicare
and Medicaid Services
|
|
DoD
|
U.S. Department of
Defense
|
|
FDA
|
Food and Drug
Administration
|
|
HHS
|
U.S. Department of
Health and Human Services
|
|
HRSA
|
Health Resources and
Services Administration
|
|
IHS
|
Indian Health Service
|
|
NIA
|
National Institute on
Aging
|
|
NIH
|
National Institutes of
Health
|
|
NSF
|
National Science
Foundation
|
|
OASH
|
Office of the
Assistant Secretary for Health
|
|
ONC
|
Office of the National
Coordinator of Health Information Technology
|
|
SAMHSA
|
Substance Abuse and
Mental Health Services Administration
|
|
VA
|
Department of Veterans
Affairs
|
References
1. Health Resources and Services Administration website. Geriatrics
& allied health: Comprehensive geriatric education programs. Available at:http://bhpr.hrsa.gov/grants/geriatrics/.
2. Bradford A, Kunik ME, Schulz P, et al. Missed and delayed diagnosis
of dementia in primary care: Prevalence and contributing factors. Alzheimer
Dis Assoc Disord, 2009; 23(4):306-314.
3. Gaugler JE, Kane RL, Kane RA, et al. Unmet care needs and key
outcomes in dementia. J Am Geriatr Soc, 2005; 53:2098-2105.
4. Mittelman MS, Haley WE, Clay OJ, et al. Improving caregiver well-being
delays nursing home placement of patients with Alzheimer disease. Neurology,
2006; 67:1592-1599.
5. Jack CR Jr, Albert M, Knopman DS, et al. Introduction to revised
criteria for the diagnosis of Alzheimer’s disease: National Institute on Aging
and the Alzheimer’s Association workgroup. Alzheimers Dement, 2011;
7:in press.
6. Johnson H, Bouman WP, Pinner G. On telling the truth in Alzheimer's
disease: A pilot study of current practice and attitudes. Int
Psychogeriatr, 2000; 12(2):221-229.
7. Chodosh J, Mittman BS, Connor KI. Caring for patients with dementia:
How good is the quality of care? Results from three health systems. J
Am Geriatr Soc, 2007; 55(8):1260-1268.
8. Cavalieri TA, Latif W, Cieselski J, Ciervo CA Jr, Forman LJ. How physicians
approach advance care planning in patients with mild to moderate Alzheimer's
disease. J Am Osteopath Assoc, 2002; 102(14):291-298.
9. Cohen CA, Pushkar D. Transitions in care: Lessons learned from a
longitudinal study of dementia care. Am J Geriatr Psychiatr, 1999;
7(2):139-146.
10. Callahan CM, Boustani MA, Unverzagt FW, et al. Effectiveness of
collaborative care for older adults with Alzheimer disease in primary care: A
randomized controlled trial. JAMA, 2006; 295:2148-57.
11. DesRoches C, Blendon R, Young J, et al. Caregiving in the
post-hospitalization period: Findings from a national survey.Nurs Econ,
2002; 20:216-221,224.
12. Mittelman MS, Roth DL, Haley WE, Zarit SH. Effects of a caregiver
intervention on negative caregiver appraisals of behavior problems in patients
with Alzheimer’s disease: Results of a randomized trial. J Gerontol:
PsycholSci, 2004; 59B: P27-P34.
13. Sörensen S, Pinquart M, Duberstein P. How effective are interventions
with caregivers? An updated meta-analysis. Gerontologist, 2002;
42(3):356-72. Available at:http://www.ncbi.nlm.nih.gov/pubmed/12040138.
14. Mittelman MS, Haley WE, Clay OJ, Roth DL. Improving caregiver
well-being delays nursing home placement of patients with Alzheimer disease. Neurol,
2006; 67(9):1592–1599.
15. Kemper P, Harriet LK, Alecxih L. Long-term care over an uncertain
future: What can current retirees expect? Inquiry, December 2005;
42(4):335-350.
16. MetLife Mature Market Institute. MetLife long-term care IQ: Removing
myths, reinforcing realities. September 2009.
17. Mathematica Policy Research, Inc. Shoring up the infrastructure for
long-term care: What do vulnerable adults know about their options? Issue
Brief, July 2004.
18. Government Accountability Office. Elder justice: Stronger federal
leadership could enhance national response to elder abuse. 2011.Available at:https://secure.ssa.gov/apps10/poms.nsf/lnx/0423022385.
Accessed November 15, 2011.
19. Blendon RJ. Georges J., et al. Key Findings from a five-country
survey of public attitudes about Alzheimer’s disease. Poster presented at AAIC,
July 2011.
20. Alzheimer’s Association. State government Alzheimer’s disease plans.
Available at: http://www.alz.org/join_the_cause_state_plans.asp.
Accessed November 28, 2011.
0 comments:
Post a Comment